Abstract:PURPOSE: The emergence of bacteria that are resistant to many currently used drugs emphasizes the need to discover and develop new antibiotics that are effective against such multi-resistant strains. Kendomycin is a novel polyketide that has a unique quinone methide ansa structure and various biological properties. This compound exhibits strong antibacterial activity against Gram-negative and Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Despite the promise of kendomycinin in several therapeutic areas, its mode of action has yet to be identified.METHODS: In this study, we used a multidisciplinary approach to gain insight into the antibacterial mechanism of this compound.RESULTS: The antibacterial activity of kendomycin appears to be bacteriostatic rather than bactericidal. Kendomycin inhibited the growth of the MRSA strain COL at a low concentration (MIC of 5 μg/mL). Proteomic analysis and gene transcription profiling of kendomycin-treated cells indicated that this compound affected the regulation of numerous proteins and genes involved in central metabolic pathways, such as the tricarboxylic acid (TCA) cycle (SdhA) and gluconeogenesis (PckA and GapB), cell wall biosynthesis and cell division (FtsA, FtsZ, and MurAA), capsule production (Cap5A and Cap5C), bacterial programmed cell death (LrgA and CidA), the cellular stress response (ClpB, ClpC, ClpP, GroEL, DnaK, and GrpE), and oxidative stress (AhpC and KatA). Electron microscopy revealed that kendomycin strongly affected septum formation during cell division. Most kendomycin-treated cells displayed incomplete septa with abnormal morphology.CONCLUSIONS: Kendomycin might directly or indirectly affect the cell division machinery, protein stability, and programmed cell death in S. aureus. Additional studies are still needed to obtain deeper insight into the mode of action of kendomycin.

Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains

Investigations to the Antibacterial Mechanism of Action of Kendomycin

A Conserved Hydrophobic Core At Bcl-X(L) Mediates Its Structural Stability And Binding Affinity With Bh3-Domain Peptide Of Pro-Apoptotic Protein

Structural Analysis of the Interaction between Bcl-xL and the Noncanonical BH3 Domain of Non-Bcl-2 Family Proteins

Complex disruption effect of natural polyphenols on Bcl-2-Bax: molecular dynamics simulation and essential dynamics study

Bcl-X(L) Forms Two Distinct Homodimers at Non-Ionic Detergents: Implications in the Dimerization of Bcl-2 Family Proteins

Evidence for the mode of action of the highly cytotoxic Streptomyces polyketide kendomycin

Covalent inhibition of pro-apoptotic BAX

Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation

BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors

Development of 3‐phenyl‐n‐(2‐(3‐phenylureido)ethyl)‐thiophene‐2‐sulfonamide Compounds As Inhibitors of Antiapoptotic Bcl‐2 Family Proteins

Therapeutics targeting BCL2 family proteins

Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells

Epothilone B Analogue (Bms-247550)-Mediated Cytotoxicity Through Induction Of Bax Conformational Change In Human Breast Cancer Cells

BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs

Synthesis and Helical Structure of Lactam Bridged BH3 Peptides Derived from Pro-Apoptotic Bcl-2 Family Proteins

Bcl-2 Family Proteins As Targets for Anticancer Drug Design

BCL-X L –targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors